A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with metastatic prostate cancer

Trial Identifier:	D3618C00002
Sponsor:	AstraZeneca
Collaborator:	PAREXEL
NCTID::	NCT04087174
Start Date:	August 2019
Primary Completion Date:	June 2021
Study Completion Date:	June 2021
Condition:	Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	Spanish Translation
	Spanish Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
ES	Barcelona, ES, 08036
US, IN	Indianapolis, IN, US, 46202
US, NE	Omaha, NE, US, 68114
US, NY	White Plains, NY, US, 10601
US, PA	Gettysburg, PA, US, 17325
US, SC	Myrtle Beach, SC, US, 29572

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company